Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products
- Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs
Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry. In response, Invaio's platform discovers and develops peptide-based crop protection solutions that complement or offer potent alternatives to conventional chemistry while meeting growers' standards for efficacy, affordability, and ease of use.
As a part of the commercialization of its peptide-based products, Invaio will leverage Ginkgo's platform and best-in-class microbial strains for protein production. Ginkgo's strains have been engineered to provide advanced starting points for protein and peptide-based products through industrial-scale fermentation. In this collaboration, Ginkgo will further optimize its strains and fermentation processes to deliver on Invaio's production goals.
"Ginkgo's technology offers us a clear path to manufacturing our peptides at scale," said
This collaboration demonstrates Invaio's commitment to developing scalable and cost effective peptide-based crop protection solutions that fits into and complements growers' existing practices. It highlights the value of Ginkgo's technologies in helping biotechnology companies efficiently optimize different stages of product development, including scale-up and manufacturing. As part of this program, Ginkgo will perform key protocols using its autonomous lab infrastructure, including Reconfigurable Automation Carts (RACs) and Catalyst automation software.
"At Ginkgo, we understand the urgency for next-generation agricultural solutions that can support growers, consumers and the planet,"
Ginkgo's platform supports partners at various stages of scale-up and manufacturing: from production strain licensing and engineering to bioprocess development and scale-up.
To learn more, visit Invaio.com or www.ginkgo.bio/
About
About
INVAIO SCIENCES CONTACT:
GINKGO BIOWORKS INVESTOR CONTACT:
GINKGO BIOWORKS MEDIA CONTACT:
Forward-Looking Statements of
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-invaio-sciences-enter-collaboration-to-develop-manufacturing-technology-for-peptide-based-agricultural-products-302691304.html
SOURCE
